Skip to main content
Official Website of Stem Cell Mexico – Since 2002
Stem Cell Therapy Mexico

What is the cost of Stem Cell Treatment for Stroke?

At Stem Cell Mexico, stem cell treatment for stroke typically costs between $7,000 and $9,500 USD.

Free Consultation
Brain location on a neutral human figure

The final price depends on the type of stroke, the time since it happened, the deficits you want to address (movement, speech, balance, cognition), the number of cells recommended, the route of administration, the level of physical support you need during your stay and how long you require medical observation. Your complete cost is confirmed in writing after a medical evaluation and before any deposit, and only the items listed in your quote are included.

Stroke recovery is a long, personal process for patients and families. Beyond the price, it is important to understand how regenerative therapy is thought to help, what clinical trials have found and how it should fit with rehabilitation. This guide covers each of these points.

Why stroke plans cost more than joint treatments

Neurological protocols generally require:

  • Larger cell doses, because the cells are delivered systemically rather than into a single small area.
  • More extensive screening, including cardiovascular risk assessment, blood work and review of brain imaging.
  • Closer medical observation, often with an overnight stay and nursing support.
  • Special accommodations, such as wheelchair-accessible transportation, help with transfers or a caregiver-friendly itinerary.

These factors explain why stroke treatment sits in a higher range than local orthopedic injections.

What the price usually includes

A typical stroke plan includes:

  • Consultation with the doctor and stem cell specialist, with review of your MRI or CT, neurology notes, rehabilitation reports and medications.
  • Pre-treatment laboratory testing (blood count, metabolic panel, urinalysis and tumor markers).
  • Allogeneic mesenchymal stromal cells (MSCs) derived from donated umbilical cord tissue, prepared for your scheduled date.
  • Administration according to your plan (most commonly intravenous infusion) under medical supervision.
  • Medical observation with nursing care, ground transportation between the San Diego airport area and the clinic, patient coordination and follow-up.

Flights, extra hotel nights and companion lodging are usually separate unless listed.

Why the price varies within the range

Type of stroke

Ischemic strokes, caused by a blocked artery, account for most strokes and are the focus of most cell therapy research. Hemorrhagic strokes, caused by bleeding, have different risks and may require additional evaluation.

Time since the stroke

Clinical trials have studied cells in the acute phase (days after stroke), the subacute phase (weeks to months) and the chronic phase (more than six months). Most people who contact us are in the chronic phase, living with persistent weakness, spasticity, speech or balance problems. Goals and protocols differ by phase.

Severity and goals

Someone with mild hand weakness who wants to regain fine motor control has a different plan from someone who is wheelchair-dependent with significant speech impairment.

Dose, route and number of sessions

Higher doses, combined routes or a plan that anticipates more than one session increase the total.

What this means: stroke recovery and where cell therapy fits

According to the World Stroke Organization, stroke is one of the leading causes of death and disability worldwide, and many survivors live with long-term limitations. Recovery depends on neuroplasticity, the brain's ability to reorganize and form new connections. The most effective tools to harness neuroplasticity remain intensive, task-specific rehabilitation (physical, occupational and speech therapy), together with secondary prevention: blood pressure control, antithrombotic medication when indicated, cholesterol management, diabetes control and lifestyle changes.

Regenerative therapy is being studied as a way to support these processes, not to replace them.

Understanding the phases of stroke recovery

Recovery after stroke follows a recognizable pattern. In the first days, the priority is emergency treatment to restore blood flow or control bleeding and to prevent complications. During the following weeks and months, the brain is most plastic, and most spontaneous recovery happens in this window, which is why early, intensive rehabilitation matters so much. After about six months, progress usually slows, but it does not stop: many people continue to improve with targeted therapy, practice and assistive strategies for years. Regenerative research is exploring whether cell-derived signals can reopen or extend some of that plasticity, especially in the chronic phase when progress has plateaued. This is an active scientific question, and it is one of the reasons why goals should be specific, measured and reviewed with your rehabilitation team.

How MSC therapy is thought to work after stroke

After a stroke, damaged brain tissue cannot simply be regrown. Mesenchymal stromal cells are investigated because they may:

  • Reduce inflammation in and around the injured area, influencing microglia and immune cells.
  • Release neurotrophic factors that support surviving neurons and the formation of new connections.
  • Promote angiogenesis, the growth of small blood vessels, improving the environment around the damaged tissue.
  • Enhance neuroplasticity, potentially making rehabilitation more effective.

After IV infusion, many cells are temporarily filtered by the lungs and other organs, and their effects are thought to come largely from systemic signaling and interaction with the immune system.

What the evidence says

Cochrane systematic review (2019): A review of seven randomized trials with 401 participants with ischemic stroke found that stem cell transplantation was associated with reduced neurological impairment on the NIH Stroke Scale. No major safety concerns were identified.

MASTERS trial (2017): Published in The Lancet Neurology, this randomized, double-blind, placebo-controlled phase 2 trial tested an IV bone-marrow-derived cell product (multipotent adult progenitor cells) given one to two days after ischemic stroke. The treatment was safe and well tolerated, with exploratory signals of benefit when given early. Exploratory analyses suggested possible benefit when cells were given earlier, which led to further trials.

What this means for you: Cell therapy for stroke has a reassuring safety profile in controlled trials and shows signals of neurological improvement, with results that vary between patients. Most trials studied acute or subacute stroke with specific products, so their results cannot be directly applied to chronic stroke or to umbilical cord MSC protocols. Responses vary considerably between individuals.

Regulatory context

No stem cell therapy is approved by the FDA or the European Medicines Agency for stroke. In Mexico, cell therapies are regulated by COFEPRIS and must come from licensed laboratories.

Who may be a candidate

Evaluation considers:

  • Type of stroke and time since it occurred, with medical stability (no recent new stroke or transient ischemic attack).
  • Current deficits and specific, measurable goals.
  • Control of risk factors: blood pressure, atrial fibrillation, diabetes and cholesterol.
  • Use of blood thinners and bleeding risk.
  • No active infection and no cancer history within the past five years.
  • Access to rehabilitation after treatment.

What results patients and families commonly ask about

Will my loved one walk or talk again? No treatment can promise this. When improvements occur, they are often gradual and partial, for example better hand control, less spasticity, improved endurance or clearer speech.

When would we see changes? Families typically assess progress over three to six months, ideally with therapist evaluations.

Should rehabilitation continue? Yes. Rehabilitation remains the most important factor in recovery, and regenerative therapy may help patients get more from it.

What can affect outcomes

  • Size and location of the stroke.
  • Time since the stroke and age.
  • Intensity and consistency of rehabilitation.
  • Control of vascular risk factors.
  • Sleep, mood, nutrition and overall health.

Preparing for treatment

Send recent brain imaging, neurology and rehabilitation reports, and a complete medication list, especially anticoagulants or antiplatelet drugs, which should never be stopped without medical guidance. Tell us about mobility needs, swallowing difficulties or communication challenges so the team can plan transportation, meals and support. Recording a short baseline, such as a walking video, grip strength or a speech sample, helps compare progress later.

Risks and limitations

IV infusions of MSCs have generally been well tolerated in trials, with possible temporary fever, headache or fatigue. Rare risks include allergic reactions, infection and thrombotic events, which is why screening and observation are important for stroke survivors. Results vary between patients.

What our patients usually receive

Based on the treatment plans our team prepares for patients, a typical protocol at Stem Cell Mexico includes:

  • Wharton's jelly MSCs by IV infusion, usually between 100 and 200 million cells, depending on the condition, body weight and medical review.
  • An additional intrathecal application (similar to an epidural, usually about 60 million cells) for some neurological conditions, only after the doctor reviews your medical reports and confirms you are a candidate.
  • One night at our facilities, sometimes two, with nursing and medical monitoring.
  • Consultation with your doctor and the stem cell specialist, pre-treatment laboratory tests and ground transportation from the San Diego airport area.
  • Complementary therapies, such as PRP, exosomes or NAD+, only when the doctor considers them useful; they are always listed in your written plan.

Recovery is gradual, and each person responds differently. Some patients begin noticing changes within the first weeks, while others notice them over the following months, which is why our team stays in contact after treatment to follow your progress and decide whether a second application could help.

Questions to ask during your evaluation

  • Which deficits is this treatment intended to support?
  • What dose and route do you recommend, and why?
  • How will you measure progress after treatment?
  • How should I coordinate this with my neurologist and therapists?
  • What exactly is included in my quote?

Bottom line

Stem cell treatment for stroke at Stem Cell Mexico typically ranges from $7,000 to $9,500 USD, reflecting larger doses, careful screening and supportive care. Clinical trials show good safety and signs of neurological improvement. A medical evaluation can help determine whether this type of regenerative treatment is appropriate for your stroke recovery, goals and medical history, and gives you a written quote before you decide.

References

  1. Cochrane: Boncoraglio GB et al. Stem cell transplantation for ischemic stroke, 2019 (opens in a new tab)
  2. Hess DC et al. Safety and efficacy of multipotent adult progenitor cells in acute ischaemic stroke (MASTERS): a randomised, double-blind, placebo-controlled, phase 2 trial. The Lancet Neurology, 2017 (opens in a new tab)
  3. World Stroke Organization (WSO): Global Stroke Fact Sheet (opens in a new tab)

Request your medical evaluation

A clearer path starts here.

Tell us a little about yourself. We’ll help you understand the next step.

Vania, patient coordinator at Stem Cell Mexico

Vania, our patient coordinator

Your questions. Your travel plans.
A real person to help.

Talk to Vania on WhatsApp (opens in a new tab)

What happens next?

  1. Your advisor contacts you.
  2. We explain the medical review.
  3. You explore your options.

Call +1 800 646 0290

Let’s begin with you.

Your inquiry starts a conversation. Treatment requires medical evaluation.

Vania · Patient Advisor

Start my free evaluation
Free Consultation